Etiopathogenesis of Parkinson disease: A new beginning?

Neuroscientist

Volumn 15, Issue 1, 2009, Pages 28-35

  Le, Weidong ^a   Chen, Shen ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dopamine neuron development; Environmental neurotoxins; Gene regulation; Transcription factors

Indexed keywords

BACTERIAL TOXIN; LIPOPOLYSACCHARIDE; MANEB; NEUROTOXIN; NUCLEAR RECEPTOR RELATED FACTOR 1; PARAQUAT; TRANSCRIPTION FACTOR;

CELL MATURATION; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; GENE CONTROL; GENETIC DISORDER; HUMAN; LATENT PERIOD; NERVE CELL DIFFERENTIATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PERINATAL PERIOD; PREGNANCY; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; BRAIN; DOPAMINE; HUMANS; NEURONS; PARKINSON DISEASE;

EID: 59149101888     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858408319974     Document Type: Review

References (90)

1. Abeliovich A., Hammond R. 2007. Midbrain dopamine neuron differentiation: factors and fates. Dev Biol 304: 447-54.
2. Alavian KN, Scholz C., Simon HH 2008. Transcriptional regulation of mesencephalic dopaminergic neurons: the full circle of life and death. Move Dis 23: 319-28.
3. Alberi L., Sgado P., Simon HH 2004. Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development 131: 3229-36.
4. Andersson E., Tryggvason U., Deng Q., Friling S., Alekseenko Z., Robert B., and others. 2006. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124: 393-405.
5. Balch WE, Morimoto RI, Dillin A., Kelly JW 2008. Adapting proteostasis for disease intervention. Science 319: 916-9.
6. Barlow BK, Cory-Slechta DA, Richfield EK, Thiruchelvam M. 2007. The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod Toxicol 23: 457-70.
7. Barlow BK, Richfield EK, Cory-Slechta DA, Thiruchelvam M. 2004. A fetal risk factor for Parkinson's disease. Dev Neurosci 26: 11-23.
8. Bergman O., Hakansson A., Westberg L., Nordenström K., Carmine Belin A., Sydow O., and others. 2008. Pitx3 polymorphism is associated with early onset Parkinson's disease. Neurobiol Aging. Epub ahead of print, 8 March 2008.
9. Blum M. 1998. A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nat Neurosci 1: 374-7.
10. Bonilla S., Hall AC, Pinto L., Attardo A., Götz M., Huttner WB, and others. 2008. Identification of midbrain floor plate radial glialike cells as dopaminergic progenitors. Glia 56: 809-20.
11. Braak H., Bohl JR, Muller CM, Rüb U., de Vos RA, Del Tredici K. 2006. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 21: 2042-51.
12. Bystron I., Blakemore C., Rakic P. 2008. Development of the human cerebral cortex: Boulder Committee revisited. Nat Rev Neurosci 9: 110-22.
13. Carvey PM, Punati A., Newman MB 2006. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 15: 239-50.
14. Castelo-Branco G., Wagner J., Rodriguez FJ, Sousa K., Rawal N., Pasolli HA, and others. 2003. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A 100: 12747-52.
15. Chew LJ, Huang F., Boutin JM, Gallo V. 1999. Identification of nuclear orphan receptors as regulators of expression of a neurotransmitter receptor gene. J Biol Chem 274 (41). 29366-75.
16. Chu Y., Kompoliti K., Cochran EJ, Mufson EJ, Kordower JH 2002. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 450: 203-14.
17. Chu Y., Le W., Kompoliti K., Jankovic J., Mufson EJ, Kordower JH 2006. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 494: 495-514.
18. Chung CY, Seo H., Sonntag KC, Brooks A., Lin L., Isacson O. 2005. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14: 1709-25.
19. Clarke G., Collins RA, Leavitt BR, Andrews DF, Hayden MR, Lumsden CJ, and others. 2000. A one-hit model of cell death in inherited neuronal degenerations. Nature 406: 195-9.
20. Cory-Slechta DA, Thiruchelvam M., Richfield EK, Barlow BK, Brooks AI 2005. Developmental pesticide exposures and the Parkinson's disease phenotype. Birth Defects Res A Clin Mol Teratol 73: 136-9.
21. Curtis MA, Faull RL, Eriksson PS 2007. The effect of neurodegenerative diseases on the subventricular zone. Nat Rev Neurosci 8: 712-23.
22. Dewing P., Chiang CW, Sinchak K., et al. 2006. Direct regulation of adult brain function by the male-specific factor SRY. Curr Biol 16: 415-20.
23. Dodson MW, Guo M. 2007. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr Opin Neurobiol 17 (3). 331-7.
24. Eells JB, Lipska BK, Yeung SK, Misler JA, Nikodem VM 2002. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced loco-motor activity. Behav Brain Res 136: 267-75.
25. Fleming SM, Fernagut PO, Chesselet MF 2005. Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2: 495-503.
26. Fuchs J., Mueller JC, Lichtner P., Schulte C., Munz M., Berg D., and others. 2008. The transcription factor Pitx3 is associated with sporadic Parkinson's disease. Neurobiol Aging. Epub ahead of print, 14 August 2007.
27. Gao FB 2008. Posttranscriptional control of neuronal development by microRNA networks. Trends Neurosci 31: 20-6.
28. Goridis C., Rohrer H. 2002. Specification of catecholaminergic and serotonergic neurons. Nat Rev Neurosci 3: 531-41.
29. Grandjean P., Landrigan PJ 2006. Developmental neurotoxicity of industrial chemicals. Lancet 368: 2167-78.
30. Grimes DA, Han F., Panisset M., et al. 2006. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord 21: 906-9.
31. Healy DG, Abou-Sleiman PM, Ahmadi KR, Gandhi S., Muqit MM, Bhatia KP, and others. 2006. NR4A2 genetic variation in sporadic Parkinson's disease: a genewide approach. Mov Disord 21: 1960-3.
32. Hegde AN, Upadhya SC 2007. The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci 30: 587-95.
33. Hermanson E., Joseph B., Castro D., Lindqvist E., Aarnisalo P., Wallén A., and others. 2003. Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp Cell Res 288: 324-34.
34. Hwang DY, Ardayfio P., Kang UJ, Semina EV, Kim KS 2003. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res 114 (2). 123-31.
35. Ibanez P., Lohmann E., Pollak P., Durif F., Tranchant C., Agid Y., et al. 2004. Absence of NR4A2 exon 1 mutations in 108 families with autosomal dominant Parkinson disease. Neurology 62: 2133-4.
36. Jacobsen KX, MacDonald H., Lemonde S., Daigle M., Grimes DA, Bulman DE, and others. 2008. A Nurr1 point mutant, implicated in Parkinson's disease, uncouples ERK1/2-dependent regulation of tyrosine hydroxylase transcription. Neurobiol Dis 29: 117-22.
37. Jankovic J. 2005. Progression of Parkinson's disease: are we making progress in charting the course ? Arch Neurol 62: 351-2.
38. Jankovic J. 2008. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79: 368-76.
39. Jankovic J., Chen S., Le WD 2005. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 77: 128-38.
40. Jiang C., Wan X., He Y., Pan T., Jankovic J., Le W. 2005. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol 191: 154-62.
41. Kim J., Inoue K., Ishii J., Vanti WB, Voronov SV, Murchison E., and others. 2007. A microRNA feedback circuit in midbrain dopamine neurons. Science 317: 1220-4.
42. Klein C., Schlossmacher MG 2007. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurol 69: 2093-104.
43. Le W., Conneely OM, He Y., Jankovic J., Appel SH 1999. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem 73: 2218-21.
44. Le W., Conneely OM, Zou L., He Y., Saucedo-Cardenas O., Jankovic J., and others. 1999. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol 159: 451-8.
45. Le W., Pan T., Huang M., Xu P., Xie W., Zhu W., Zhang X., Deng H., Jankovic J. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci 2008 ; 273: 29-33.
46. Le WD, Xu, P., Jankovic, J., Jiang H., Appel SH, Smith RG, and others. 2003. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33: 85-9.
47. Lee MA, Lee HS, Lee HS, Cho KG, Jin BK, Sohn S., and others. 2002. Overexpression of midbrain-specific transcription factor Nurr1 modifies susceptibility of mouse neural stem cells to neurotoxins. Neurosci Lett 333: 74-8.
48. Leenders KL, Salmon EP, Tyrrell P., Perani D., Brooks DJ, Sager H., and others. 1990. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47: 1290-8.
49. Levesque D., Rouillard C. 2007. Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci 30: 22-30.
50. Ling Z., Zhu Y., Tong C., Snyder JA, Lipton JW, Carvey PM 2006. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol 199: 499-512.
51. Ling ZD, Chang Q., Lipton JW, Tong CW, Landers TM, Carvey PM 2004. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 124: 619-28.
52. Liu Z., Wang X., Yu Y., Li X., Wang T., Jiang H., and others. 2008. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 5: 2693-8.
53. Logroscino G. 2005. The role of early life environmental risk factors in Parkinson disease: what is the evidence ? Environ Health Perspect 113: 1234-8.
54. Maden M. 2007. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci 8: 755-65.
55. Martinat C., Bacci JJ, Leete T., Kim J., Vanti WB, Newman AH, and others. 2006. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc Natl Acad Sci U S A 103: 2874-9.
56. Martyn CN, Osmond C. 1995. Parkinson's disease and the environment in early life. J Neurol Sci 132: 201-6.
57. McNaught KSP, Jenner P., Olanow CW 2007. Protein mishandling: role of the ubiquitin proteasome system in the pathogenesis of Parkinson's disease. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. 5 th ed. Philadelphia: Lippincott Williams and Wilkins. p 33-49.
58. Mages HW, Rilke O., Bravo R., Senger G., Kroczek RA 1994. NOT, a human immediate-early response gene closely related to the steroid/thyroid hormone receptor NAK1/TR3. Mol Endocrinol 8: 1583-91.
59. Melrose HL, Lincoln SJ, Tyndall GM, Farrer MJ 2006. Parkinson's disease: a rethink of rodent models. Exp Brain Res 173 (2). 196-204.
60. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. 1994. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208-10.
61. Moore DJ, West AB, Dawson VL, Dawson TM 2005. Molecular pathophysiology of Parkinson's disease Annu Rev Neurosci 28: 57-87.
62. Nichols WC, Uniacke SK, Pankratz N., Reed T., Simon DK, Halter C., and others. 2004. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov Disord 19: 649-55.
63. Nunes I., Tovmasian LT, Silva RM, Burke RE, Goff SP 2003. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A 100 (7). 4245-50.
64. Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, and others. 2003. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 53: 624-9.
65. Pan T., Kondo S., Le W., Jankovic J. 2008. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. Epub ahead of print, 10 January 2008.
66. Parish CL, Castelo-Branco G., Rawal N., Tonnesen J., Sorensen AT, Salto C., and others. 2007. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest 118: 149-60.
67. Park CH, Kang JS, Shin YH, Chang MY, Chung S., Koh HC, and others. 2006. Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons. Faseb J 20: 2553-5.
68. Peng C., Fan S., Li X., Fan X., Ming M., Sun Z., and others. 2007. Overexpression of pitx3 upregulates expression of BDNF and GDNF in SH-SY5Y cells and primary ventral mesencephalic cultures. FEBS Lett 581: 1357-61.
69. Reuhl KR 1991. Delayed expression of neurotoxicity: the problem of silent damage. Neurotoxicology 12: 341-6.
70. Riaz SS, Bradford HF 2005. Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: applications in cell replacement treatment for Parkinson's disease. Prog Neurobiol 76: 257-78.
71. Saucedo-Cardenas O., Quintana-Hau JD, Le WD, Smidt MP, Cox JJ, De Mayo F., and others. 1998. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A 95: 4013-8.
72. Schapira AHV. 2008. Mitochondria in the aethiology and pathogenesis of Parkinson's disease. Lancet Neurol 7: 97-107.
73. Schimmel JJ, Crews L., Roffler-Tarlov S., Chikaraishi DM 1999. 4.5 kb of the rat tyrosine hydroxylase 5′ flanking sequence directs tissue specific expression during development and contains consensus sites for multiple transcription factors. Brain Res Mol Brain Res 74: 1-14.
74. Scott B., Jankovic J. 1996. Delayed-onset progressive movement disorders. Neurology 46: 68-74.
75. Sgado P., Alberi L., Gherbassi D., Galasso SL, Ramakers GM, Alavian KN, and others. 2006. Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice. Proc Natl Acad Sci U S A 103: 15242-7.
76. Smidt MP, Burbach JP 2007. How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci 8: 21-32.
77. Smits SM, Smidt MP 2006. The role of Pitx3 in survival of midbrain dopaminergic neurons. J Neural Transm Suppl 70: 57-60.
78. Sulzer D. 2007. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30: 244-50.
79. Tan EK, Chung H., Chandran VR, Tan C., Shen H., Yew K., and others. 2004. Nurr1 mutational screen in Parkinson's disease. Mov Disord 19: 1503-5.
80. Thiruchelvam M., McCormack A., Richfield EK, Baggs RB, Tank AW, Di Monte DA, and others. 2003. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 18: 589-600.
81. Thorsen P., Jensen IP, Jeune B., Ebbesen N., Arpi M., Bremmelgaard A., and others. 1998. Few microorganisms associated with bacterial vaginosis may constitute the pathologic core: a population-based microbiologic study among 3596 pregnant women. Am J Obstet Gynecol 178: 580-7.
82. Trinh K., Moore K., Wes PD, Muchowski PJ, Dey J., Andrews L., and others. 2008. Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J Neurosci 28 (2). 465-72.
83. van den Munckhof P., Luk KC, Ste-Marie L., Montgomery J., Blanchet PJ, Sadikot AF, and others. 2003. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130: 2535-42.
84. Volpicelli F., Caiazzo M., Greco D., Consales C., Leone L., Perrone-Capano C., and others. 2007. BDNF gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. J Neurochem 102: 441-53.
85. Wang G., van der Walt JM, Mayhew GL, Li YJ, Züchner S., Scott WK, and others. 2008. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82: 283-9.
86. Wijemanne S., Jankovic J. 2007. Hemiparkinsonism-hemiatrophy syndrome. Neurol 69: 1585-94.
87. Xu PY, Liang R., Jankovic J., Hunter C., Zeng YX, Ashizawa T., and others. 2002. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurol 58: 881-4.
88. Zetterstrom RH, Solomin L., Jansson L., Hoffer BJ, Olson L., Perlmann T. 1997. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276: 248-50.
89. Zetterstrom RH, Williams R., Perlmann T., Olson L. 1996. Cellular expression of the immediate early transcription factors Nurr1 and NGFIB suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res Mol Brain Res 41: 111-20.
90. Zheng K., Heydari B., Simon DK 2003. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch Neurol 60: 722-5.